Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06230198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

Study acronym: TheRAPy
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 4, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 2025 to Jan 2026 · Start date changed from estimate of Nov 2024 to Dec 4, 2024 · Site details revised at 4 of 4 sitesv5 Show 3 more changesShow less
    • Primary completion date: Sep 2025 to Jan 2026
    • Start date changed from estimate of Nov 2024 to Dec 4, 2024
    • Site details revised at 4 of 4 sites
  2. Study sites: 3 to 4v4
  3. Study sites: 0 to 3 Primary completion date: Apr 2025 to Sep 2025 · Completion date: Aug 2025 to Nov 2026 · Start date: Oct 2024 to Nov 2024v3 Show 3 more changesShow less
    • Primary completion date: Apr 2025 to Sep 2025
    • Completion date: Aug 2025 to Nov 2026
    • Start date: Oct 2024 to Nov 2024
  4. Start date: May 2024 to Oct 2024 Primary endpoint revised · Primary completion date: Oct 2024 to Apr 2025 · Completion date: Mar 2025 to Aug 2025 · 3 morev2 Show 6 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Oct 2024 to Apr 2025
    • Completion date: Mar 2025 to Aug 2025
    • Interventions: retrograde autologous priming (RAP) (Procedure) to Crystalloid priming (Procedure), retrograde autologous priming (RAP) (Procedure)
    • Secondary endpoint revised
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
Trial Details
NCT Number NCT06230198
Lead Sponsor Population Health Research Institute
Conditions Red Blood Cell Transfusion
Enrollment 4,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov